Join The Discussion

 

Fort Worth's new thoroughfare plan aims for more variety in street design

Fort Worth is launching a review of its master thoroughfare plan aimed at accommodating continued suburban growth and central city redevelopment with a greater variety of streets and more efficient traffic flow.

read more >

Holt Hickman, businessman who helped preserve Stockyards, dies at 82

Longtime Fort Worth businessman, philanthropist and preservationist Holt Hickman died Nov. 15, 2014, at the age of 82.

read more >

UPDATE: Could American Airlines move its headquarters?

A key linchpin in the Fort Worth economy, American Airlines Group Inc., is considering sites for a new headquarters, possibly outside the city, the airline’s CEO said this morning.

read more >

Crestwood area hoping to block planned office building

Residents of West Fort Worth’s Crestwood Association are trying to block the rezoning of a small apartment complex at White Settlement Road and North Bailey Avenue to make way for a planned office building, saying it would represent the start of commercial encroachment into their neighborhood.

read more >

Tiger Woods takes a swing at Fort Worth's Dan Jenkins - in print anyway

Rarely does Golf Digest make the news. Leave it to Dan Jenkins to change that.

read more >

Former TECH Fort Worth client raises $107M in IPO

ZS Pharma Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, raised nearly $107 million on the NASDAQ capital market from its initial public offering on June 18.
ZS Pharma, a Texas Emerging Technology Fund awardee based in Coppell, also granted the underwriters a 30-day option to purchase up to an additional 891,667 shares of common stock at the IPO price, less underwriting discounts and commissions. The offering is expected to close on or about June 23, subject to customary closing conditions.


ZS Pharma received a $2 million TETF award in 2010 for its development of an orally available sorbent product, ZS-9, which was designed to remove excess potassium from the blood and maintain normal potassium levels. This technology could potentially be used to treat hyperkalemia, a condition that can lead to irregular heartbeat and sudden cardiac death. ZS Pharma was a client of TECH Fort Worth.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the IPO. BMO Capital Markets Corp. is lead manager and William Blair & Co. LLC is co-manager.
ZS Pharma Inc. is traded under the symbol ZSPH.

Betty Dillard
bdillard@bizpress.net


 

< back

Email   email
hide
Midterms
What was the message of the midterm elections?